Study of radioactive PSMA-targeting treatment for advanced prostate cancer
Part of Cancer clinical trials.
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread (metastatic) and is no longer responding to hormone suppression and/or chemotherapy
- Your scan shows strong PSMA signal on a 68Ga-PSMA PET/CT within about 1 week before the treatment
- Your scan should NOT show FDG-positive tumors that don’t have corresponding PSMA uptake (the target must match)
- You have not had other radiation/“radioisotope” cancer treatments in the last 6 months
- Your blood counts and organ function are strong enough: hemoglobin at least 9.0, white blood cells at least 2.5×10^9/L, platelets at least 100×10^9/L, and kidney function (creatinine) not above 100 μmol/L
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a PSMA-targeted treatment using 177Lu can help men with prostate cancer that has spread and is growing despite hormone treatment. It may help if your scan shows high PSMA in the tumor and your blood counts and organ function are adequate.
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This early-phase study tests a new radioactive drug that targets PSMA, a protein on prostate cancer cells, to see if it can shrink tumors and slow the disease. It may be an option for men with advanced prostate cancer that has not responded to hormone therapy and possibly chemotherapy.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.